GLP-1 Receptor Agonists and SGLT2 Inhibitors: Don’t Sugarcoat the Costs!

The cost of diabetes in the United States has nearly doubled over the past decade in part due to rising prices and the cost of newer medications used to manage the disease.  With new, improved, but costly alternatives available, it’s going to be challenging for ambulatory care practitioners to evaluate if the potential benefits of using these newer medication classes as first-line therapy (instead of metformin) outweigh their big price tag.

Guest Authors:  Amanda Smith, PharmD and Nicole Slater, PharmD, BCACP

Music by Good Talk